A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
PD-1 drugs set to have their stomach cancer wings clipped
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
A failed trial is a failed trial, says China’s regulator
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
